On April 21, 2022 Galen, a global pharmaceutical company, and part of the Almac Group headquartered in Craigavon, reported that a new partnership with Sunstar Suisse S.A. to exclusively distribute and commercialise GelX Oral Spray in the United Kingdom and Ireland (Press release, Almac, APR 21, 2022, View Source [SID1234612716]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
GelX OralSpray is a product designed to treat Oral Mucositis (OM), a painful inflammation of the lining of the mouth and throat often caused by radiation and chemotherapy cancer treatments.1 OM increases the likelihood of infection and puts severely immunocompromised patients at risk of sepsis and septicemia.2 The collaboration with Galen will ensure that this oncology supportive care product is readily available in a hospital setting for direct use by clinicians to improve the quality of life of their patients.
Galen, which has successfully launched over 100 products in more than 25 locations across the world in a range of areas including medical nutrition, pain management, dermatology and gastroenterology, has developed a global expansion strategy of its product portfolio. This partnership extends the company’s UK and Ireland offering to more treatment areas, providing Galen with a growing hospital portfolio which now includes oncology supportive care as well as respiratory disease and Emergency Medicine.
Galen’s Managing Director and President, Dr Dennise Broderick, said: "Galen is recognised as a partner of choice for specialty pharma companies to launch and promote their products within the UK, Ireland, Europe, US and other global regions."
"We continually invest in building a portfolio of innovative branded products with global potential in existing and new markets. This new partnership with Sunstar Suisse S.A. to supply GelX Oral Spray, along with the recent announcement of our distribution agreement for Provocholine (methacholine chloride) are evidence of our ongoing commercial success and expertise."